Abstract
High cholesterol is often a prerequisite for atherosclerotic plaque. Low-density lipoprotein cholesterol (LDL-C) is the focus of the National Cholesterol Education Program Adult Treatment Panel guidelines. LDL-C ranges from 50 to 70 mg/dL in native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals, who are notably free of atherosclerotic vascular disease. Multiple statin trials and meta-analyses support a treatment target of LDL-C levels less than 70 mg/dL, as this is associated with improved clinical outcomes and atherosclerosis regression. In fact, no threshold has yet been identified below which patients do not benefit from lowering of LDL-C.
Original language | English (US) |
---|---|
Pages (from-to) | 13-26 |
Number of pages | 14 |
Journal | Medical Clinics of North America |
Volume | 96 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2012 |
Keywords
- Atherosclerosis
- Coronary risk
- Low-density lipoprotein cholesterol
- Statins
ASJC Scopus subject areas
- Medicine(all)